Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.52 |
| ▸ | TDO2 | P48775 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20602729 | 1.00 | IDO1 (0.52) | IDO1TDO2CYP3A4 | |
| SCHEMBL20621024 | 0.82 | IDO1 (0.62) | IDO1TDO2CYP3A4 | |
| SCHEMBL20621023 | 0.82 | IDO1 (0.62) | IDO1TDO2CYP3A4 | |
| SCHEMBL20602751 | 0.82 | IDO1 (0.62) | IDO1TDO2CYP3A4 | |
| SCHEMBL20602670 | 0.79 | IDO1 (0.58) | IDO1TDO2CYP3A4 | |
| SCHEMBL20602779 | 0.77 | IDO1 (0.45) | IDO1TDO2CYP3A4 | |
| SCHEMBL20602777 | 0.77 | IDO1 (0.45) | IDO1TDO2CYP3A4 | |
| SCHEMBL20602807 | 0.77 | IDO1 (0.45) | IDO1TDO2CYP3A4 | |
| SCHEMBL30649064 | 0.77 | IDO1 (0.45) | IDO1TDO2CYP3A4 | |
| SCHEMBL30649222 | 0.76 | IDO1 (0.43) | IDO1TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CYP3A4 428/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CYP3A4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.